{
    "nct_id": "NCT04626895",
    "official_title": "Measuring the Efficacy of Paxman Scalp Cooling to Prevent Chemotherapy Induced Alopecia (CIA) in Black Patients With Stage I-III Breast or Gynecological Cancers",
    "inclusion_criteria": "* Stage I-III breast cancer patients\n* Stage I-III endometrial cancer patients\n* Stage I-III ovarian cancer patients\n* Self-identified as black: African, African-American, or Caribbean black are included . Patients of mixed race who identify as black are also included.\n* Planned for >4 cycles of chemotherapy in the neoadjuvant or adjuvant setting with curative intent\n* At least one chemotherapy agent being a taxane.\n* Ability to read and answer questions in English\n* Ability to sign informed consent for themselves.\n* Able to fit into one of available cap sizes\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Metastatic cancer patients\n* Patients who do not self-identify as black (see definition above)\n* History of cryoglobulinemia or cold agglutin disease\n* Prior chemotherapy\n* Non-taxane chemotherapy regimens (anthracycline based chemotherapy regimens are eligible for breast cancer patients)\n* Baseline alopecia\n* Concurrent medications to prevent hair loss\n* Cold urticaria and cold- induced anaphylaxis\n* Unable to fit into an available cap size\n* Adults unable to consent on their own will not be eligible\n* Individuals unable to answer questionnaires in English will not be eligible.\n* Pregnant women will not be permitted to enroll as the use of this device in pregnancy is not well studied\n* Prisoners will not be included in this study.",
    "miscellaneous_criteria": ""
}